With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...
Despite the known risks of patients experiencing life-threatening side effects, prescribing standards vary widely among ...
There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
Eisai to Divest Rights for Pariet in China to Peak Pharma TOKYO, Apr 1, 2025 - (JCN Newswire) - Eisai Co., ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in the ...
BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.
The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback